Health Security, Critical Medicines and Biomanufacturing
Medicines, APIs, Diagnostics, Vaccines and Bioindustrial Resilience as Strategic European Assets
23 pages · PDF · 04 July 2026 · Licensed single-user copy, watermarked to the buyer
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Europe’s health-security problem is no longer confined to hospitals, reimbursement systems or pharmaceutical demand. It is an industrial-capacity question.
The availability of essential medicines, active pharmaceutical ingredients, antibiotics, vaccines, diagnostics and medical devices now depends on regulated production sites, upstream inputs, qualified suppliers, data infrastructures, public procurement mechanisms and emergency manufacturing capacity that can withstand external shocks.
Key questions this report answers
- Why is Europe's health-security problem now an industrial-capacity question rather than a hospital or reimbursement one?
- What European legal and institutional architecture governs critical medicines and biomanufacturing?
- Which critical value chains, including APIs, antibiotics, vaccines, and diagnostics, show patterns of dependence?
- Which European companies, assets, and programmes reduce that dependence?
Inside this report
- Health security as an industrial question
- The European legal and institutional architecture
- Critical value chains and the pattern of dependence
- European companies, assets and programmes that reduce dependence
Who it's for
Strategy, corporate-development and investment teams that need an ecosystem-level view — budgets, industrial capacity and technology landscapes — before committing capital or capacity.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (04 July 2026). You receive a 23-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Strategic reports · Military Medical Tech · Synthetic Biology · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →